# Gluconeogenic control of Dravet Syndrome

> **NIH NIH R01** · UNIVERSITY OF COLORADO DENVER · 2022 · $158,867

## Abstract

The goal of this administrative supplement is to request the purchase of a critical instrument (Seahorse XF24e,
Agilent Technologies) which is necessary for the continuation and completion of the project. To achieve the
major aims and goals of the parent project are to study metabolic defects in a devastating neurodevelopmental
disease known as Dravet Syndrome. A key assay that we have developed for this project is assessment of
metabolic defects in a zebrafish model of the disease. The assay involves the use of an extracellular flux analyzer
that measures mitochondrial and glycolytic functions in real time in live zebrafish larvae. The instrument is
requested to replace a new version of a previous model which has been retired by the company.

## Key facts

- **NIH application ID:** 10624665
- **Project number:** 3R01HD102071-03S1
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** Scott C Baraban
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $158,867
- **Award type:** 3
- **Project period:** 2020-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10624665

## Citation

> US National Institutes of Health, RePORTER application 10624665, Gluconeogenic control of Dravet Syndrome (3R01HD102071-03S1). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10624665. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*